tbuckley/cabot-search huggingface dataset:
AB0026 A Simple Method of Removing Low Density Granulocytes from Peripheral Blood Mononuclear Cells in Autoimmune Diseases
Authors: S. Zhang, H. Shen
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Low density granulocytes (LDGs) can form neutrophil extracellular traps (NETs) spontaneously and excessively. When peripheral blood mononuclear cells (PBMCs) were used for studying T lymphocytes, PBMCs-contained LDGs may decrease the threshold of activating T lymphocytes by forming NETs. <h3>Objectives</h3> This study focused on profiles of LDGs in common autoimmune diseases and method of removing LDGs from PBMCs. <h3>Methods</h3> LDGs percentages in PBMCs from 55 dermatomyositis (DM) patients, fifteen polymyositis (PM) patients, forty-two rheumatoid arthritis (RA) patients, twenty-five SLE patients and 19 healthy controls were tested by flow cytometer. Increasing relative centrifugal force (RCF) method, PBMCs adherence method and whole blood sedimentation method were used to remove LDGs from PBMCs. PBMCs from six patients with positive T-SPOT.<i>TB</i> were adhered one hour and then tested for T-SPOT.<i>TB</i> again. <h3>Results</h3> Compared with controls (1.28±0.73%), patients with DM (8.41±10.87%, P&lt;0.0001), PM (8.41±10.39%, P&lt;0.0001), RA (4.05±6.97%, P=0.0249) and SLE (7.53±11.52%, P=0.0006) showed significantly higher LDGs percentage in PBMCs. Increasing RCF in a limited range can decrease LDGs percentage for cases with high LDGs percentages, but not remarkably increase LDGs clearance rate. PBMCs adherence method can significantly remove LDGs and scarcely influence the T lymphocyte percentage in PBMCs compared to whole blood sediment method. T-SPOT.<i>TB</i> value significantly decreased after LDGs were removed from PBMCs by using the PBMCs adherence method. <h3>Conclusions</h3> Similar to SLE, LDG percentages in PBMCs were significantly increased in patients with DM, PM and RA. LDGs9 influences on T lymphocytes cannot be ignored in PBMCs culture. PBMCs adherence method was a simple and easy-to-use method of removing LDGs from PBMCs. <h3>Disclosure of Interest</h3> None declared
Multi-Targeted Receptor Tyrosine Kinase Inhibitor, ABT-869, Induces Apoptosis and Suppresses Proliferation of Ba/F3 FLT-3 ITD Mutant Cells in Vitro and in Vivo through Inhibition of FLT3 and AKT.
Authors: Jenny E Hernandez, Joan Zape, Keith Glaser, Elliot Landaw, Cecilia Fu, Kathleen M. Sakamoto
Journal: Blood (2008)
Increased Effector CD4+ T-Cells Early Post Hematopoietic Stem Cell Transplantation Using an Alemtuzumab-Based Reduced Intensity Conditioning Regimen Correlate with Subsequent Development of Graft Versus Host Disease.
Authors: Katie Matthews, ZiYi Lim, Laurence Pearce, Khalid Tobal, Alejandro Madrigal, Ghulam J. Mufti, Linda D. Barber
Journal: Blood (2007)
AB0286 Clinical Features and Therapeutic Considerations in Elderly Patients with Rheumatoid Arthritis; A Cross-Sectional Study: Table 1.
Authors: N. Alpay Kanıtez, S. Çelik, Ö. Pehlivan, S. Yılmaz Öner, C. Bes
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis (RA)9s prevalence increases with age. The average life expectancy is getting longer and global population is becoming older. Physicians will be challenged with the recognition and treatment of RA patients who may have different physical conditions, comorbid diseases and using multi-drugs. <h3>Objectives</h3> The aim of this study was to evaluate the clinical characteristics and treatment modalities in elderly RA patients. <h3>Methods</h3> We assessed elderly RA patients (≥65 years) diagnosed according to 2010 American College of Rheumatology (ACR) criteria. Clinical and laborotary findings, treatment durations, dose of drugs and treatment related adverse effects were recorded into a pre-defined protocol. "Disease Activity Score" (DAS-28), "Physician Global Assessment" (PGA) and "Health Assessment Questionnaire" (HAQ) scores were used as composite indices for RA activity evaluation. <h3>Results</h3> Seventy-four RA patients [54 patients (73%) were female] with a mean age of 71±5 (65–86) years were included into the study,. The mean total disease duration of these patients was 97±104 (9–600) months. Disease onset was in the elderly period for 40 (55%) patients. Small joints of hands were the most frequently involved joints (95%). Seropositivity rate was 66% and 56% of the patients had erosive disease. DAS-28 and HAQ scores were correlated with PGA scores (p:0,001). The proportion of patients with high and moderate disease activity was found as 79% according to DAS-28 scores. There was no association between age and antibody titers or activity indices. Non-steroidal antiinflammatory drugs (NSAIDs) were part of the treatment in 53 patients (71%) and no severe side effects associated with NSAIDs were observed. The mean cumulative prednisolone dose was 7617±10602 mg. Hypertension and osteoporosis were the most frequent comorbidities (64% and 48%, respectively). The most commonly used disease modifying antirheumatic drug (DMARD) was methotrexate (76%) and the rate of compliance was found high for all drugs except sulfasalazine (Table 1). While 60% of all patients were treated with DMARD monotherapy, combination DMARD therapy were used in 37% of patients. The rate of biologic theraphy was found as 12% (9 patients) in all study population. <h3>Conclusions</h3> In this preliminary data from our ongoing study, elderly RA patients had remarkable compliance with NSAIDs and DMARDs. Although patients treated with biologic agents constituted a small group, no serious side effect that required cessation of the treatment was observed. By the increasing numbers of elderly RA patients in our cohort, we expect to obtain more powerful data on compliance and safety issues of the treatment and particularly biologic agents. <h3>Disclosure of Interest</h3> None declared
Re-Exposure of Cord Blood (CB) to Non-Inherited Maternal HLA Antigens (NIMA) Improves Transplant Outcome in Patients (pts) with Hematologic Malignancies and May Reduce Relapse.
Authors: Jon J van Rood, Cladd E Stevens, Jacqueline Smits, Carmelita Carrier, Carol Carpenter, Andromachi Scaradavou
Journal: Blood (2009)
Response to Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis. Diabetes Care 2016;39:1108–1114
Authors: Ele Ferrannini, Michael Mark, Eric Mayoux
Journal: Diabetes Care (2016)

Jordan et al. (1) propose a further loop to the β-hydroxybutyrate hypothesis by recalling that atrial natriuretic peptide (ANP) induces an increase in lipid oxidation and a ketone response by virtue of its intrinsic lipolytic properties. Elegant work in healthy subjects has found that graded infusions of ANP, raising circulating ANP levels up to 10-fold, are associated with enhanced lipolysis and lipid oxidation rates with no change in energy expenditure (2). The highest intravenous dose of ANP also lowered blood pressure (3)—to a similar extent as do sodium–glucose cotransporter 2 (SGLT2) inhibitors—through increased …
Correlation Between Peripheral Blood Counts and Extent of Bone Marrow Infiltration in Chronic Lymphocytic Leukemia
Authors: Wei Ding, Sara J Achenbach, Kari G. Chaffee, Timothy G. Call, Sameer A. Parikh, Susan M. Schwager, Jose F. Leis, Asher Chanan-Khan, Deborah A. Bowen, Michael Conte, Susan L. Slager, Kay Medina, Neil E. Kay, Tait D. Shanafelt
Journal: Blood (2015)
THU0277 Evaluation of Polymorphisms of STAT4, TRAF31P2 and HCP5 in Sjögren Syndrome: Association with Disease Susceptibility and Clinical Aspects:
Authors: S. Colafrancesco, C. Perricone, R. Priori, G. Picarelli, C. Ciccacci, P. Borgiani, A. Latini, G. Novelli, G. Valesini
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Primary Sjögren syndrome (pSS) is a systemic inflammatory condition characterized by lymphocytic infiltrates in exocrine glands. STAT4 is one of the genes involved in "interferon (IFN) signature" and a single nuclear polymorphism (SNP), rs7574865 has been found associated with pSS. Other SNPs in TRAF3IP2 (rs33980500 and rs13193677) and HCP5 (rs3099844) genes, have been previously associated with the susceptibility to systemic lupus erythematosus (SLE), and seem to influence the disease phenotype. <h3>Objectives</h3> To evaluate the association of different SNPs [STAT4 (rs7574865), TRAF3IP2 (rs33980500), HCP5 (rs3099844)] with the susceptibility to pSS and their role in modulation of clinical and laboratory features. <h3>Methods</h3> One hundred thirty-five consecutive patients with pSS (AECC) were enrolled and clinical and laboratory data collected. Three hundred age and sex-matched healthy subjects were used as controls. Genomic DNA was isolated from peripheral blood mononuclear cells (Qiagen blood DNA mini kit). Genotyping was performed by allelic discrimination assays (Applied Biosystems, Foster City, CA, USA). <h3>Results</h3> Clinical and laboratory features are reported in table. Deviations from Hardy–Weinberg equilibrium were not observed. The SNPs rs7574865 of STAT4 and rs3099844 of HCP5 were found associated with pSS at both the genotypic and allelic level (p&lt;0.001, OR=1.84, 95%CI=1.28–2.65 and p&lt;0.05, OR=2.28, 95%CI=1–3.7, respectively) and the data was confirmed after adjustment for other variables. STAT4 was found associated with the presence of monoclonal component (p=0.021). HCP5 was associated with the presence of leukopenia (p=0.021, OR=2.91, 95%CI=1.15–7.38) and lymphoma (p&lt;0.001). <h3>Conclusions</h3> This study confirms the association between the rs7574865 polymorphism of STAT4 and the susceptibility for pSS, and shows for the first time the association with a variant of HCP5. STAT4 was associated with monoclonal component supporting the role of IFN signature in autoantibodies production. Furthermore, HCP5 seem to be able to influence the disease phenotype predisposing to the development of leukopenia and lymphoma. These data need to be validated on larger cohorts of patients. <h3>Disclosure of Interest</h3> None declared
Pharmacogenomic Factors Such as the Expression of Imatinib Transporters (OCT-1, ABCB-1 and ABCG-2) at Diagnosis, OCT-1 SNPs, and Steady-State Imatinib and Desmethyl-Imatinib Trough Plasma Levels in De Novo Chronic Phase Chronic Myelogenous Leukemia, May Influence Disease Response to Imatinib
Authors: Hélène Labussière, Sandrine Hayette, Kaddour Chabane, Marie-Claude Gagnieu, Quoc-Hung Lê, Isabelle Tigaud, Joëlle Bernard, Fiorenza Barraco, Jean-Pierre Magaud, Mauricette Michallet, Franck E Nicolini
Journal: Blood (2008)
αIIbβ3 Variants Defined By Next Generation Sequencing: Implications for Predicting Variants Likely to Cause Glanzmann Thrombasthenia and Alloimmune Disorders
Authors: Claudia Lorena Buitrago, Augusto Rendon, Ernest Turro, Yupu Liang, Ilenia Simeoni, Ana Negri, ThromboGenomics Consortium, Marta Filizola, Willem H. Ouwehand, Barry S. Coller
Journal: Blood (2014)
Patients with atopic dermatitis with filaggrin loss-of-function mutations show good but lower responses to immunosuppressive treatment
Authors: E. Roekevisch, M.M.G. Leeflang, M.E. Schram, L.E. Campbell, W.H. Irwin McLean, S. Kezic, J.D. Bos, P.I. Spuls, M.A. Middelkamp-Hup
Journal: British Journal of Dermatology (2016)

between FLG mutation status and treatment success are necessary to confirm these findings.
Human Endothelial Progenitor Cells: A Novel and Promising Cellular Therapy for Regenerating Intestinal Mucosa.
Authors: Josh A. Wood, Evan Colletti, Laura E. Mead, David A. Ingram, Christopher D Porada, Esmail Zanjani, Mervin C. Yoder, Graca Almeida-Porada
Journal: Blood (2008)
Natural Killer (NK) Cell Reconstitution After Haploidentical Unmanipulated Bone Marrow Transplantation with Reduced Intensity Conditioning
Authors: Isabel Gonzalez-Gascon y Marin, Ana Maria Perez-Corral, Jorge Gayoso, Javier Anguita, Cristina Pascual, Mi Kwon, David Serrano, Gabriela Rodriguez-Macias, Pascual Balsalobre, Jose Luis Diez-Martin
Journal: Blood (2011)
Kinetics of BCR-ABL Mutant Clones Determines Resistance in CML on Second Generation TKI Treatment.
Authors: Franz X Gruber, Thomas Ernst, Jaqueline Maier, Martin C. Müller, Ingvild Mikkola, Kimmo Porkka, Dietger Niederwieser, Andreas Hochhaus, Thoralf Lange
Journal: Blood (2008)
Final appeal seeks to block minimum alcohol price in Scotland
Authors: Bryan Christie
Journal: BMJ (2016)

A final legal challenge is to be made to try to block the introduction in Scotland of a minimum price on a unit of alcohol, in a move that has been roundly condemned by health campaigners.

The Scotch Whisky Association, which has fought the measure through the courts for three years, has decided to make a last ditch appeal to the UK Supreme Court. This follows a ruling in the Scottish Court of Session in October rejecting the association’s case that minimum pricing was incompatible with European …
A Medical Home Model with Overlap of Pediatric and Adult Care Mitigates the Upsurge in Health Care Utilization Post-Transfer to Adult Care in Sickle Cell Disease
Authors: Jane S. Hankins, Sheila Anderson, Matthew P Smeltzer, Kerri Nottage, Mark Yancy, Bryan Winter, Robin Womeodu, Yvonne M. Carroll, Nada Elmagboul
Journal: Blood (2014)
SAT0301 Prevalence of Abortions and Fetal Atrioventricular Block in Patients with Positive Anti-RO and Anti-LA Antibodies
Authors: F.M. Ortiz Sanjuan, J. Ivorra Cortés, L. González Puig, I. Chalmeta Verdejo, E. Grau Garcia, C. Feced Olmos, E. Labrador Sánchez, K. Arévalo Ruales, R. Negueroles Albuixech, J. Fragio Gil, I. Martínez Cordellat, J. Valero Sanz, C. Alcañiz Escandell, C. Nájera Herranz, G. Poveda Marín, J. Román Ivorra
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Anti-SSA/Ro and anti-SSB/La antibodies are present in inflammatory autoimmune disease patient sera, and there are related to different clinical manifestations. It is well known the association between the presence of these antibodies in maternal blood and fetal atrioventricular block. However, there are no much studies about infertility or repeated abortions and anti-SSA/Ro and anti-SSB/La antibodies in broad series. <h3>Objectives</h3> To characterise a cohort of patients with positive anti-SSA/Ro and/or anti-SSB/La antibodies and to evaluate the prevalence of abortions and neonatal mortality. <h3>Methods</h3> Observational descriptive study with 162 patients older than 15 years old with pregnancies history and positive anti-SSA/Ro and/or anti-SSB/La antibodies from February 2011 to July 2015. We consider healthy women with pregnancies history and with comparable characteristics as negative control group. <h3>Results</h3> We included 162 patients with positive anti-SSA/Ro and/or anti-SSB/La antibodies with a mean age of 50.5±14.2 years old. Main diagnosis were systemic lupus erythematosus (n=85), Sjögren syndrome (n=40), rheumatoid arthritis (n=16), systemic sclerosis (n=6), mixed connective tissue disease (n=3) and other diagnosis (n=12). Lupus anticoagulant was positive in 8 cases and 57 patients showed low complement values. 37% of patients had at least one pregnancy, and the 36.7% aborted during pregnancy. There were no significant differences in the abortion incidence between our cohort of patients and the healthy control group considered. We observed 4 cases of fetal atrioventricular block, all of them with positive anti-SSA/Ro and/or anti-SSB/La antibodies and only in one case also with positive lupus anticoagulant. <h3>Conclusions</h3> In our series, pregnant women with positive anti-SSA/Ro and/or anti-SSB/La antibodies did not show high prevalence of abortion. However, the positivity of these antibodies was statistically correlated with the presence of fetal atrioventricular block. <h3>Disclosure of Interest</h3> None declared
Therapeutic Targeting of the Hypoxic Microenvironment in Acute Lymphocytic Leukemia.
Authors: Marina Konopleva, Juliana Benito, Yue-Xi Shi, Sergej Konoplev, Steven M. Kornblau, Olga Frolova, Patrick A. Zweidler-McKay, YiHua Qiu, William R. Wilson, Dario Campana, Rodrigo Jacamo, Hongbo Lu, Wendy Fang, Gautam Borthakur, Carlos E. Bueso-Ramos, Hagop M. Kantarjian, Deborah A. Thomas, Michael Andreeff
Journal: Blood (2009)
Detection of drug‐responsive B lymphocytes and antidrug IgG in patients with β‐lactam hypersensitivity
Authors: M. O. Amali, A. Sullivan, R. E. Jenkins, J. Farrell, X. Meng, L. Faulkner, P. Whitaker, D. Peckham, B. K. Park, D. J. Naisbitt
Journal: Allergy (2016)

Delayed-type β-lactam hypersensitivity develops in subset of patients. The cellular immunological processes that underlie the drug-specific response have been described; however, little is known about involvement of the humoral immune system. Thus, the aim of this study was to utilize piperacillin hypersensitivity as an exemplar to (i) develop cell culture methods for the detection of drug-specific B-cell responses, (ii) characterize drug-specific IgG subtypes and (iii) assess reactivity of IgG antibodies against proteins modified to different levels with piperacillin haptens.IgG secretion and CD19+ CD27+ expression on B cells were measured using ELISPOT and flow cytometry, respectively. A piperacillin-BSA adduct was used as an antigen in ELISA antibody binding studies. Adducts generated using different ratios of drug to protein were used to determine the degree of conjugation required to detect IgG binding.B cells from hypersensitive patients, but not controls, were stimulated to secrete IgG and increase CD27 expression when cultured with soluble piperacillin. A piperacillin-BSA adduct with cyclized and hydrolysed forms of the hapten bound to eight lysine residues was used to detect hapten-specific IgG 1-4 subclasses in patient plasma. Hapten inhibition and the use of structurally unrelated hapten-BSA adducts confirmed antigen specificity. Antibody binding was detected with antigens generated at piperacillin/BSA ratios of 10:1 and above, which corresponded to a minimum epitope density of 1 for antibody binding.These data show that antigen-specific B lymphocytes and T lymphocytes are activated in piperacillin-hypersensitive patients. Further work is needed to define the role different IgG subtypes play in regulating the iatrogenic disease.
Lenalidomide reexposure After Short Interruption In Del(5q) MDS Patients at Relapse of Transfusion Dependence
Authors: Robert Marek Radkowski, Sabine Haase, Brigitte Schlegelberger, Gudrun Goehring, Stefanie Banisch, Michael Heinsch, Carlo Aul, Aristoteles Giagounidis
Journal: Blood (2010)
Topical Progesterone Cream Does Not Increase Thrombotic and Inflammatory Factors in Postmenopausal Women.
Authors: Kenna Stephenson, Carol Price, Anna Kurdowska, Pierre Neuenschwander, John Stephenson, Barbara Pinson, Douglas Stephenson, Denita Alfred, Agnieszka Krupa, Debra Mahoney, David Zava, Mary Bevan
Journal: Blood (2004)
AB0039 Interleukin-17 in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients: Correlation with Clinical Presentation, Laboratory Parameters and Activity Indices
Authors: R.F. Moftah, E.H.E.-S. Hassan
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Serum interleukin (IL)-17 concentrations have been reported to be increased in systemic lupus erythematosus (SLE), but associations with clinical characteristics are not well understood. Autoimmune diseases such as RA, classically believed to be Th1-mediated, are predominantly driven by a Th17 immune response. <h3>Objectives</h3> this study aimed to compare the serum levels of IL-17 in patients with SLE and RA, it is correlation with clinical presentations, laboratory findings and disease activity in both diseases. <h3>Methods</h3> The study was carried out on 3 groups. Group I: 20 patients with SLE. Group II: 20 patients with RA. Group III: 10 of age and sex matched healthy subjects as control group. <h3>Results</h3> In this study, the mean of age were 43.1±8.98, 46.8±8.17 and 41.98±8.25 for group I (SLE), II (RA) and III (control) respectively, with no statistical significant differences between the studied groups. Also, there were no statistical significant differences between the three studied groups regarding sex, disease duration, disease activity, laboratory investigations (except HB, WBC and platelet count). The mean of IL-17 were 173.2±52.11, 82.6±48.17 and 73.07±41.05 for group I (SLE), II (RA) and III (Control) respectively, group I have values statistically higher than other groups, and group II have values statistically higher than group III. Serum IL-17 levels were significantly higher in SLE patients compared to healthy group. <h3>Conclusions</h3> Serum IL-17 concentration correlates with SLE and RA diseases activity but is significantly elevated in patients with SLE disease. The association of other cytokines with serum IL-17 suggests that IL-17 may drive activation of diverse immune pathways in SLE and RA. <h3>Disclosure of Interest</h3> None declared
FRI0454 Endothelial Dysfunction in Psoriatic Arthritis: Evaluation by Endothelial-Dependent Flow-Mediated Dilation and Coronary Flow Reserve
Authors: G. Murdaca, G. Bezante, E. Penza, M. Balbi, S. Negrini, F. Puppo
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Patients with psoriatic arthritis (PsA) are at an increased risk for premature cardiovascular disease (CVD) independent of traditional risk factors [1]. Endothelial dysfunction plays a central role in the development of accelerated atherosclerosis. <h3>Objectives</h3> To evaluate endothelial dysfunction by assessment of artery endothelial-dependent flow-mediated dilation (FMD) and coronary flow reserve (CFR). <h3>Methods</h3> 20 patients (12 males and 8 females – age 57,5 ±10,8 years) affected by PsA according to CASPAR criteria [2] were enrolled. The 10-years cardiovascular Framigham risk score was calculated. Ultrasound assessment of brachial artery FMD was performed according to Corretti et al. [3]. CFR was evaluated by contrast-enhanced Doppler echocardiography and dipyridamole administration as previously described [4]. <h3>Results</h3> The 10-years cardiovascular Framingham risk score of PsA patients (mean 3.84 ± 3.22) was in the low risk range. The assessment of brachial artery FMD showed a significant reduction of post-ischemic vasodilation in PsA patients (mean -17.70 ± 16%) as compared with normal population (mean +15.00 ± 5%). Coronary flow reserve was under the normal range (CFR &gt;2.5) [5] in 15/20 PsA patients. <h3>Conclusions</h3> The present results demonstrate that PsA patients with low cardiovascular Framingham risk score have increased arterial stiffness and decreased coronary arteries flow reserve. These data suggest that endothelial dysfunction may underlie premature atherosclerosis in PsA patients <h3>References</h3> Ogdie A et al., Ann Rheum Dis 2015; 74: 326–32. Taylor W et al., Arthritis Rheum 2006; 54: 2665–73. Corretti MC et al., J Am Coll Cardiol 2002; 39: 257–6. Sulli A et al., Rheumatology 2004; 43: 505–9. Caiati C et al., Circulation 1999; 99: 771–8. <h3>Acknowledgement</h3> This work is supported by Pfizer <h3>Disclosure of Interest</h3> None declared
Pegfilgrastim (Neulasta®) and Filgrastim (Neupogen®) Use in Patients Receiving Chemotherapy in Oncology Practices: Interim Results of the Assessment of Current CSF Evaluation for Proper Therapy (ACCEPT) Study.
Authors: Luis Alberto Meza, Veena Charu, Roger Dansey, Fang Xie, Bradley Stolshek
Journal: Blood (2004)